ABBV vs BA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Boeing Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-07.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
The Boeing Company · Industrials
$234.54
+45.0% upside to fair value
Grade C
QuantHub Verdict
BA has more upside to fair value
(+45.0%).
BA trades at a lower forward P/E
(96.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
BA |
| Current Price |
$261.07 |
$234.54 |
| Fair Value Estimate |
$264.30 |
$340.08 |
| Upside to Fair Value |
+1.2%
|
+45.0%
|
| Market Cap |
$461.3B |
$184.9B |
| Forward P/E |
128.0x
|
96.9x
|
| EV / EBITDA |
31.0x
|
30.4x
|
| Price / Sales |
7.3x
|
2.0x
|
| Price / FCF |
22.1x
|
-177.6x
|
| Revenue Growth YoY |
+12.4%
|
+14.0%
|
| Gross Margin |
70.7%
|
4.8%
|
| Operating Margin |
27.6%
|
-5.9%
|
| Return on Equity |
68.0%
|
-8723.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
—
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
The Boeing Company operates in the Industrials sector within the Aerospace & Defense industry, manufacturing commercial jetliners, defense, space, and security systems. Despite a challenging operating margin of -5.9% and a negative free cash flow per share of -2.46, Boeing shows strong recent earnings growth of 89.2% and revenue growth of 14.0% in the most recent quarter, signaling a potential re…
Accumulation Zones
| Metric |
ABBV |
BA |
| Zone Low |
$198.23 |
$255.06 |
| Zone High |
$224.66 |
$289.07 |
| In Buy Zone? |
No
|
Yes
|